ImmuPharma's Lupuzor succeeds in Phase II lupus trial
This article was originally published in Scrip
ImmuPharmahas announced positive interim results of its Phase IIb study of its T-cell inhibitor Lupuzor (IPP-201101) for the treatment of systemic lupus erythematosus. The London-based company is preparing to progress the drug into Phase III development in the next six months.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.